Thursday 7 May, 2026
Introduction / Objective Abrocitinib is an oral selective Janus kinase 1 (JAK1) inhibitor approved for the treatment of moderate-to-severe atopic…
Read morePoster: Drug/Disease Modelling - Absorption & PBPK
Physiologically-based pharmacokinetic modeling to predict human toxicokinetics of the synthetic cannabinoid 5F-Cumyl-P7AICA and its major metabolite: from pig to human translation
Thursday 7 May, 2026
Introduction: New psychoactive substances (NPSs) have attracted significant attention from public health authorities due to their growing use as alternatives…
Read moreA FIT-FOR-PURPOSE PHYSIOLOGICALLY BASED PHARMACOKINETIC APPROACH FOR INTRANASAL ANALGESICS: APPLICATION TO KETAMINE AND FENTANYL ANALOGS
Thursday 7 May, 2026
Introduction/Objectives: Intranasal delivery is widely used for rapidly acting analgesics in emergency and perioperative settings. Lipophilic weak bases such as…
Read morePhysiologically-based pharmacokinetic model to predict loading dose polymyxin B exposure in critically ill patients with sepsis
Thursday 7 May, 2026
Objectives: Polymyxin B (PMB) is among the few antibiotics retaining activity against carbapenem-resistant Gram-negative pathogens [1], yet its pharmacokinetics (PK)…
Read moreUNDERSTANDING THE ORAL BIOAVAILABILITY OF VORICONAZOLE: A STEP TOWARDS A COMPREHENSIVE CYP2C19‑ AND CYP3A4‑MEDIATED DRUG‑DRUG‑GENE INTERACTION NETWORK
Thursday 7 May, 2026
Voriconazole (VRC) is a second-generation triazole antifungal with broad-spectrum activity, and remains a cornerstone of antifungal therapy, particularly for invasive…
Read morePrediction of Hydroxyurea Pharmacokinetics and Dose Adjustment in Children with Mild, Moderate, and Severe Renal Impairment Using Physiologically Based Pharmacokinetic Modeling
Thursday 7 May, 2026
Background Hydroxyurea is the cornerstone disease-modifying therapy for sickle cell disease (SCD) in pediatric populations. Kidney involvement is a recognized…
Read moreDevelopment of a physiologically-based pharmacokinetic model to characterize the drug-drug interaction of the inhaled compound CHF6001 as a victim of CYP3A4 inhibitors
Thursday 7 May, 2026
Objectives: CHF6001 is a PDE4 inhibitor that was specifically designed to be delivered via inhalation [1]. In vitro data showed…
Read moreReconstruction of an Advanced Dissolution, Absorption, and Metabolism (ADAM) Model in R: Structural Comparison with Simcyp and PK-Sim
Thursday 7 May, 2026
Objectives: Physiologically based pharmacokinetic (PBPK) models are widely used to characterize oral drug absorption, yet important structural differences exist between…
Read morePHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING OF LOSARTAN FOR THE PREDICTION OF DRUG-DRUG- AND DRUG-GENE-INTERACTIONS
Thursday 7 May, 2026
Introduction: According to the World Health Organization, losartan is considered an Essential Medicine and ranks among the ten most frequently…
Read morePHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING FOR SUB-SAHARAN AFRICAN POPULATIONS: A REVIEW OF SYSTEM PARAMETERS AND VARIABILITY DRIVERS.
Thursday 7 May, 2026
Background. Physiologically based pharmacokinetic (PBPK) models generate exposure predictions from drug-specific parameters interacting with system (population) inputs such as organ…
Read more